Diverse antigens and autoantibodies

Diverse antigens and autoantibodies is a broad descriptive category rather than a specific molecular target or receptor. It encompasses a wide variety of substances that the immune system recognizes as foreign (antigens) or self-derived molecules that are pathologically targeted by the host's own immune system (autoantibodies). Antigens are typically proteins, glycoproteins, or polysaccharides that bind to specific receptors on B and T lymphocytes, thereby initiating an immune response (Janeway's Immunobiology, 9th edition, 2016). Autoantibodies are immunoglobulins produced by B cells that mistakenly react with the body's own tissues, serving as a hallmark of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis (Rose & Bona, Nature Medicine, 1993). Because this category includes thousands of distinct molecular entities, it does not represent a single therapeutic target; instead, it describes the collective targets of broad-spectrum immunotherapies. For instance, intravenous immunoglobulin (IVIG) is used to neutralize a diverse array of pathogenic autoantibodies, while therapies like rituximab target the B cells responsible for producing them (Lünemann et al., Journal of Clinical Investigation, 2015). In clinical diagnostics, specific antigens and autoantibodies are used as biomarkers to identify infections or monitor the progression of autoimmune conditions (NIH, StatPearls, 2023).

Other names

AutoantigensSelf-antigensExogenous antigensPathogenic immunoglobulinsMultiple antigens

Broad-spectrum neutralization of circulating antibodies, depletion of antibody-producing cells, or inhibition of the complement cascade triggered by antigen-antibody complexes.